Hepatitis C: Is eradication possible?

ESCMID Study Group for Viral Hepatitis (ESGVH)

Research output: Contribution to journalReview article

Abstract

Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs, with more than 70 million people infected worldwide. In the resolution, "Transforming our world: the 2030 Agenda for Sustainable Development" was included as a focus area in the health-related goal with world leaders pledging to "combat" it by 2030. In response, WHO drafted the Global Viral Hepatitis Strategy carrying the ambitious targets to reduce the number of deaths by two-thirds and to increase treatment rates up to 80%. Despite the availability of highly effective therapeutic regimens based on direct-acting antivirals many barriers to HCV eradication still remain. They are related to awareness of the infection, linkage to care, availability of the therapeutic drug regimens and reinfection. Overall, if an effective prophylactic vaccine will not be available, HCV eradication appears difficult to achieve in the future.

Original languageEnglish
JournalLiver International
DOIs
Publication statusE-pub ahead of print - Nov 25 2018

Fingerprint

Hepatitis C
Conservation of Natural Resources
Hepatitis
Antiviral Agents
Vaccines
Economics
Morbidity
Costs and Cost Analysis
Mortality
Health
Therapeutics
Infection
Pharmaceutical Preparations

Cite this

Hepatitis C : Is eradication possible? / ESCMID Study Group for Viral Hepatitis (ESGVH).

In: Liver International, 25.11.2018.

Research output: Contribution to journalReview article

ESCMID Study Group for Viral Hepatitis (ESGVH). Hepatitis C: Is eradication possible? Liver International. 2018 Nov 25. https://doi.org/10.1111/liv.14011
ESCMID Study Group for Viral Hepatitis (ESGVH). / Hepatitis C : Is eradication possible?. In: Liver International. 2018.
@article{1fb276db549d4fc8a2811544313fd152,
title = "Hepatitis C: Is eradication possible?",
abstract = "Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs, with more than 70 million people infected worldwide. In the resolution, {"}Transforming our world: the 2030 Agenda for Sustainable Development{"} was included as a focus area in the health-related goal with world leaders pledging to {"}combat{"} it by 2030. In response, WHO drafted the Global Viral Hepatitis Strategy carrying the ambitious targets to reduce the number of deaths by two-thirds and to increase treatment rates up to 80{\%}. Despite the availability of highly effective therapeutic regimens based on direct-acting antivirals many barriers to HCV eradication still remain. They are related to awareness of the infection, linkage to care, availability of the therapeutic drug regimens and reinfection. Overall, if an effective prophylactic vaccine will not be available, HCV eradication appears difficult to achieve in the future.",
author = "{ESCMID Study Group for Viral Hepatitis (ESGVH)} and Andrea Lombardi and Mondelli, {Mario U}",
note = "{\circledC} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2018",
month = "11",
day = "25",
doi = "10.1111/liv.14011",
language = "English",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Hepatitis C

T2 - Is eradication possible?

AU - ESCMID Study Group for Viral Hepatitis (ESGVH)

AU - Lombardi, Andrea

AU - Mondelli, Mario U

N1 - © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2018/11/25

Y1 - 2018/11/25

N2 - Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs, with more than 70 million people infected worldwide. In the resolution, "Transforming our world: the 2030 Agenda for Sustainable Development" was included as a focus area in the health-related goal with world leaders pledging to "combat" it by 2030. In response, WHO drafted the Global Viral Hepatitis Strategy carrying the ambitious targets to reduce the number of deaths by two-thirds and to increase treatment rates up to 80%. Despite the availability of highly effective therapeutic regimens based on direct-acting antivirals many barriers to HCV eradication still remain. They are related to awareness of the infection, linkage to care, availability of the therapeutic drug regimens and reinfection. Overall, if an effective prophylactic vaccine will not be available, HCV eradication appears difficult to achieve in the future.

AB - Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs, with more than 70 million people infected worldwide. In the resolution, "Transforming our world: the 2030 Agenda for Sustainable Development" was included as a focus area in the health-related goal with world leaders pledging to "combat" it by 2030. In response, WHO drafted the Global Viral Hepatitis Strategy carrying the ambitious targets to reduce the number of deaths by two-thirds and to increase treatment rates up to 80%. Despite the availability of highly effective therapeutic regimens based on direct-acting antivirals many barriers to HCV eradication still remain. They are related to awareness of the infection, linkage to care, availability of the therapeutic drug regimens and reinfection. Overall, if an effective prophylactic vaccine will not be available, HCV eradication appears difficult to achieve in the future.

U2 - 10.1111/liv.14011

DO - 10.1111/liv.14011

M3 - Review article

C2 - 30472772

JO - Liver International

JF - Liver International

SN - 1478-3223

ER -